Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421954 · ClinicalTrials.gov registry record · Phase 3
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
A Phase 3 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00421954: Completed Phase 3 study, sponsored by New York State Psychiatric Institute.
NCT00421954 is a Phase 3 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421954, a Phase 3 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for 7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically appropriate, they may also stay at the New York State Psychiatric Institute (NYSPI) Schizophrenia Research Unit (SRU) inpatient facility.
Interventions
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00421954 record still lists
NCT00421954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone is the first listed.
NCT00421954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00421954 about?
NCT00421954 is a clinical study titled "Open-label Ziprasidone Study for Psychosis Treatment in Adolescents". This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for 7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically appropriate, they may also ...
What is the current status of trial NCT00421954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2006-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00421954?
The interventions under investigation include: Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00421954?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00421954's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia